Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study |
| |
| Authors: | Ricardo?L.?Favaretto,Atessa?Bahadori,Romain?Mathieu,Andrea?Haitel,Bernhard?Grubmüller,Vitaly?Margulis,Jose?A.?Karam,Morgan?Rouprêt,Christian?Seitz,Pierre?I.?Karakiewicz,Isabela?W.?Cunha,Stenio?C.?Zequi,Christopher?G.?Wood,Alon?Z.?Weizer,Jay?D.?Raman,Mesut?Remzi,Nathalie?Rioux-Leclercq,Solene?Jacquet-Kammerer,Karim?Bensalah,Yair?Lotan,Alexander?Bachmann,Michael?Rink,Alberto?Briganti,Shahrokh?F.?Shariat mailto:sfshariat@gmail.com" title=" sfshariat@gmail.com" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author |
| |
| Affiliation: | 1.Department of Urology,A. C. Camargo Hospital,S?o Paulo,Brazil;2.Department of Urology and Comprehensive Cancer Center,Medical University of Vienna, Vienna General Hospital,Vienna,Austria;3.Department of Urology,Rennes University Hospital,Rennes,France;4.Department of Pathology,Medical University Vienna,Vienna,Austria;5.Department of Urology,University of Texas Southwestern Medical Center at Dallas,Dallas,USA;6.Department of Urology,MD Anderson Cancer Center,Houston,USA;7.Academic Department of Urology, Faculté de Médecine Pierre et Marie Curie, La Pitié-Salpetrière Hospital, Assistance Publique-H?pitaux de Paris,University Paris 6,Paris,France;8.Cancer Prognostics and Health Outcomes Unit,University of Montreal Health Centre,Montreal,Canada;9.Department of Urology,University of Michigan Cancer Center,Ann Arbor,USA;10.Division of Urology,Penn State Milton S. Hershey Medical Center,Hershey,USA;11.Department of Pathology,Rennes University Hospital,Rennes,France;12.Department of Urology,University Hospital Basel,Basel,Switzerland;13.Department of Urology,University Medical Center Hamburg-Eppendorf,Hamburg,Germany;14.Department of Urology,Vita Salute San Raffaele University,Milan,Italy;15.Department of Urology,Weill Cornell Medical College,New York,USA |
| |
| Abstract: | ![]()
Purpose To assess the role of E-cadherin as prognostic biomarker in upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients.Methods Immunohistochemistry technique was used to evaluate E-cadherin expression in 678 patients with unilateral, sporadic UTUC treated with RNU. E-cadherin expression was considered decreased if 10 % or more cells had decreased expression (<90 %).ResultsDecreased E-cadherin expression was observed in 353 patients (52.1 %) and was associated with advanced pathological stage (P < 0.001), higher grade (P < 0.001), lymph node metastasis (P = 0.006), lymphovascular invasion (P < 0.001), concomitant carcinoma in situ (P < 0.001), multifocality (P = 0.004), tumor necrosis (P = 0.020) and sessile architecture (P < 0.001). Within a median follow-up of 30 months (interquartile range 15–57), 171 patients (25.4 %) experienced disease recurrence and 150 (21.9 %) died from UTUC. In univariable analyses, decreased E-cadherin expression was significantly associated with worse recurrence-free survival (P < 0.001) and cancer-specific survival CSS (P = 0.006); however, in multivariable analyses, it was not (P = 0.74 and 0.84, respectively). The lack of independent prognostic value of E-cadherin remained true in all subgroup analyses.ConclusionIn UTUC patients treated with RNU, decreased E-cadherin expression is associated with features of biologically and clinically aggressive disease and worse outcome in univariable, but not multivariable, analyses. If E-cadherin’s association with factors of advanced disease is confirmed on UTUC biopsy specimens, it could be used to help in the clinical decision-making regarding kidney-sparing approaches and/or neo-adjuvant chemotherapy. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
